Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that testosterone replacement therapy, especially intramuscular administration, significantly increased PSA levels compared to placebo, while a significant correlation between PSA and testosterone was observed in non-BPH patients.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This meta-analysis suggests that individuals with vertex baldness may have a higher risk of prostate cancer, though overall baldness is not significantly associated with prostate cancer risk.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

This study found that prostate size varies significantly among different ethnic groups in South-Kivu, with the Lega having larger prostate volumes compared to other groups.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This article proposes that androgenic alopecia might be an evolutionary mechanism for reducing prostate cancer risk by enhancing UV absorption, rather than being a risk factor.

This review examines advances in computer-aided drug design for targeting membrane proteins in prostate cancer but reports no new clinical results; it emphasizes the potential of structural insights and compound screening for therapeutic development.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

This study found that among men over 70, certain genetic variants associated with skin pigmentation affect serum PSA levels, with implications for how sun sensitivity and exposure may influence prostate cancer risk.

This abstract reports funding sources for ongoing research and does not present any study results.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

Finasteride treats hair loss but may affect prostate cancer detection.

This laboratory study found that PI extract, along with its metabolites Ang and Mac, inhibited cell proliferation and protein expression linked to pathways involved in BPH, suggesting potential for therapeutic use, although the Ang-Mac combination showed no significant effect on apoptosis through the p53 pathway.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.